West Introduces New NovaPure® Components

Annual Meeting of the Parenteral Drug Association (PDA) -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today introduced a new line of high-quality components under its NovaPure brand at the PDA Annual Meeting. Through a product development process that incorporates Quality by Design principles, NovaPure components, including serum and lyophilization stoppers and syringe plungers, will help to ensure the safety, efficacy and purity of injectable drug products.

“Quality by Design is an essential element in helping pharmaceutical manufacturers meet regulatory guidelines for safety and efficacy,” said Donald E. Morel, Jr., Ph.D., West's Chairman and CEO. “West is embedding QbD in manufacturing from raw materials through delivery. NovaPure components incorporate a variety of high-quality processes and features designed to ensure component reliability and provide an unrivaled level of quality for our customers, which ultimately can aid in the safety and efficacy of their drug product for the patient.”

NovaPure components:
  • Help pharmaceutical companies lower total cost of ownership
  • Will improve transparency between component and pharmaceutical manufacturers
  • Ensure quality driven by patients’ needs
  • Are manufactured with the deepest product and process understanding

For NovaPure components, West developed a comprehensive quality target product profile (QTPP) based on the needs of its customers and their end users. Critical quality attributes (CQAs), determined with the patient in mind, have been built into the development process to help ensure quality, safety and efficacy throughout a drug product’s lifecycle. Features and processes that help to ensure reliability include:
  • FluroTec® barrier film – a proven, effective barrier against extractables that provides lubricity without the need for silicone oil
  • Validated wash and sterilization processes that help ensure consistency of stopper preparation
  • 100 percent vision verification to assure low particles
  • Lot-to-lot extractable profile to assure material consistency

NovaPure components are available globally with reduced lead time and are provided in optimized packaging that helps ease transition through manufacturing environments. The components are supported by a series of unique service features that help assure the latest compliance and customer satisfaction requirements are met.

For more information, please visit www.WestNovaPure.com.

About West

West’s innovative system, device and component solutions help improve the safety and administration of injectable drugs. West’s proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2011 totaled US$1.2 billion.

West supports its customers from sales, manufacturing, customer support and research and development from locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at www.westpharma.com and www.westPFSsolutions.com. Follow us on Twitter: www.twitter.com/WestPharma.

NovaPure and FluroTec are trademarks or registered trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions. FluroTec technology is licensed from Daikyo Seiko, Ltd.

Copyright Business Wire 2010